Connect with us


Coronary Stents Market to Reach US$ 8,414.5 Mn by 2026 Driven by the High Prevalence of Coronary Arterial Disorders by 2025


The Global Coronary Stents Market potential has widened due to recent technological advancements. According to a report published by Fortune Business Insights, titled “Coronary Stents Market Size, Share and Global Trend by Deployment (Self and Balloon-expandable), Stent Type (Drug Eluting Stent, Bioresorbable Stent, Bare Metal Stent, Covered Stent and Others), End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Catheterization Labs) and Geography Forecast till 2025,” the market was valued at US$ 5,244.9 Mn in 2017.

According to Fortune Business Insights, the market will reach US$ 8,414.5 Mn by the end of 2025, exhibiting a CAGR of 6.1%

Browse Complete Report Details @

Coronary stents possess the ability to enhance severe surgical procedures such as percutaneous coronary intervention (PCI) or angioplasty. The use of coronary stents in regulating the blood supply to the heart has created a huge emphasis on the manufacture of highly efficient products. Coronary stents are inserted into the human arteries to ensure smooth blood supply to the heart. As coronary stents are mostly made up of medical-grade stainless steel, the margin for error is almost zero or minimum.

Coronary stents allow minimally invasive surgical procedures, thereby leading to a huge uptake among end users, globally. Surgical procedures using coronary stents are carried out in a much shorter time and with less discomfort than the procedures such as coronary bypass surgeries. The aforementioned factors will contribute to the growth of the global market and will enable the increase in the global coronary stents market value in the forthcoming years.

Some of the Main Key Players Covered in the Report:

  • Biotronik
  • Cardinal Health
  • Cook Medical
  • C R Bard
  • MicroPort Scientific Corp
  • Terumo Corporation
  • BKK B. Braun Melsungen AG
  • Abbott
  • Boston Scientific
  • Medtronic

Sample PDF Brochure @

Technological Advancements in Products to Enable Coronary Stents Market Growth

Recent product advancements have created a rising uptake of coronary stents in heart-related surgical procedures. In 2018, Medtronic launched a new 2 mm coronary stent for small vessels. The company also announced that it has received approval from the Food and Drug Administration (FDA) or the usage of its latest product.

The Resolute Onyx 2.0 was a new drug eluting stent which was introduced as the smallest stent available in the market at the time of its launch. Fortune Business Insights predicts that increasing the introduction of technologically advanced products will favor the growth of the global coronary stents market in the coming years.

Growing Regulatory Approvals Will Lead to Substantial Coronary Stents Market Growth

The high prevalence of coronary arterial diseases has opened up a huge coronary stents market potential. Resulting from the high demand for coronary stents, several companies have shifted their focus on developing technologically advanced stents with the aim of serving a wider audience.

The coronary stents market trends such as incorporation of micro-sized stents and use of minimally invasive procedures have contributed to the market growth. In recent years, regulatory authorities have eased off on their reluctance to approve coronary stents market products. Abbott’s CE approval for Xience Sierra was a game changer in the coronary stents industry as the device received worldwide allocates for its exceptional functional operations.

Fortune Business Insights predicts that with Xience, Abbott will account for substantial coronary stents market growth and will encourage other companies operating in the market.
Besides Abbott, some of the key players that have contributed to the increase in the coronary stents market size are Medtronic, Terumo Corporation, C. R. Bard, Inc., Cardinal Health, Boston Scientific Corporation, B. Braun Melsungen AG, MicroPort Scientific Corporation, Cook, and Biotronik SE and Co. KG.

More Trending Topics from Future Business Insights:

Breast Cancer Therapeutics Market Share, Trends, Segmentation, Future Demands Forecast (2019-2026)

Ophthalmic Lasers Market to Exhibit 5.3% CAGR Owing to Growing Global Demand for Medical Lasers by 2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us

Fortune Business Insights Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune – 411045, Maharashtra, India.


US: +1 424 253 0390

UK: +44 2071 939123

APAC: +91 744 740 1245

Email: [email protected]


VentureIsrael Launches New Venture Capital Fund


VentureIsrael announced today the launch of a new venture capital fund, which will invest in Israel based, early stage deep-tech start-ups. The fund investment strategy focuses on the companies with clear-cut technological advantages, an experienced management team and a flexible business strategy.

The fund first investments are a secure quantum communications system, an AI market research solution and a next-generation correspondent banking platform.

VentureIsrael is managed by five partners “ all investment experts with diverse backgrounds: Michael Harte – former COO of Santander UK and Barclays; Roman Gold, Gadi Isaev and Alexander Zarankin of JSCapital “ the Israeli investment platform; and Igor Turkin of Investment Management Group.

The Israeli innovation industry is demonstrating phenomenal growth potential even given the current turbulent economic environment, said Roman Gold. In the first half of 2020, Israeli start-ups attracted a record of $5.25 billion investment capital, while the total amount of exits approached $7 billion. We also see that the demand for early-stage capital is growing faster than the amount of the funding available “ therefore our aim is to find the right place in that niche of the market.

Being a part of Israeli start-up ecosystem and having closed large number of successful investment deals, we have consistently observed the importance of a clear technological advantage in a companys ability to stand out from the competition. Thats the reason our funds investment strategy will focus on deep-tech companies, said Gadi Isaev.

VentureIsrael will also pay close attention to the Enterprise Software segment of Israeli early stage start-ups. Worldwide, we see in increasing corporate demand for digital transformation. The Israeli market has long established itself as an influential and effective provider of innovative solutions for the corporate segment and our fund will seek out the best opportunities in that field, said Igor Turkin.

VentureIsraels initial closing has attracted substantial attention from private and institutional investors globally. The fund headquarters are based in Tel-Aviv, with an international subsidiary in London.

The fund final closing is expected in the first half of 2021.

For press inquiries or additional information, please contact:

Gadi Isaev


[email protected]

Continue Reading


Global Artificial Ligaments and Tendons Market- Featuring Artelon, Cousin-Biotech, FX Solutions, and GROUP FH ORTHO Among Others


The artificial ligaments and tendons market is poised to grow by USD 15.54 million during 2020-2024, progressing at a CAGR of over 11% during the forecast period.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Download Free Sample Report on COVID-19 Recovery Analysis

The report on the artificial ligaments and tendons market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by advantages of artificial ligaments.

The artificial ligaments and tendons market analysis include the application segment and geography landscape. This study identifies the growing interest in R&D of tissue-engineered ligaments as one of the prime reasons driving the artificial ligaments and tendons market growth during the next few years.

This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.

The Artificial Ligaments and Tendons Market covers the following areas:

Artificial Ligaments and Tendons Market Sizing

Artificial Ligaments and Tendons Market Forecast

Artificial Ligaments and Tendons Market Analysis

Companies Mentioned

  • Artelon, Cousin-Biotech
  • FX Solutions
  • LARS
  • Mathys AG Bettlach
  • MorphoMed GmbH
  • Orthomed
  • Xiros Ltd.


Key Topics Covered:




  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
  • Value Chain Analysis


  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024
  • Market outlook


  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition


  • Market segmentation by application
  • Comparison by application
  • Knee injuries – Market size and forecast 2019-2024
  • Shoulder injuries – Market size and forecast 2019-2024
  • Foot and ankle injuries – Market size and forecast 2019-2024
  • Other injuries – Market size and forecast 2019-2024
  • Market opportunity by application



  • Geographic segmentation
  • Geographic comparison
  • Europe – Market size and forecast 2019-2024
  • Asia – Market size and forecast 2019-2024
  • North America – Market size and forecast 2019-2024
  • ROW – Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity



  • Market drivers
  • Market challenges


  • Growing interest in R&D of tissue-engineered ligaments
  • Focus on development of 3D-printed human ligaments and tendons
  • Focus on biomechanical investigations of tendons and ligaments


  • Overview
  • Landscape disruption
  • Competitive scenario


  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Artelon
  • Cousin-Biotech
  • FX Solutions
  • LARS
  • Mathys AG Bettlach
  • MorphoMed GmbH
  • Orthomed
  • Xiros Ltd.


  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors


About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]


Continue Reading


Silver Bull Announces Closing of Initial Tranche of Private Placement For US$1.70 Million



VANCOUVER, British Columbia, Oct. 27, 2020 — Silver Bull Resources, Inc. (TSX: SVB; OTCQB: SVBL) (“Silver Bull” or the “Company”) is pleased to announce that it has completed the initial tranche of its previously announced private placement (the “Private Placement”). The initial tranche consisted of 3,623,580 units (the “Units”) of the Company at a price of US$0.47 per Unit for aggregate gross proceeds of US$1,703,083. Each Unit consists of one share of common stock in the Company (a “Common Share”) and one half of one transferable Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder to acquire one Common Share at a price of US$0.59 per Common Share until the fifth anniversary of closing of the initial tranche of the Private Placement.

Directors and management (and their affiliates) of the Company are purchasing 1,159,000 Units (approximately US$545,000) in the Private Placement.

The net proceeds of the Private Placement will be used by Silver Bull for general working capital purposes. The Company paid an aggregate finder’s fee on the initial tranche of the Private Placement of US$26,000 (1.5%).  

The second tranche of 319,000 Units (US$149,930) is expected to close on or about November 6, 2020.

All securities issued pursuant to the Private Placement are subject to a hold period under applicable Canadian securities laws, which will expire four months plus one day from the date of closing of the Private Placement, and will be restricted securities for purposes of U.S. securities laws.

The securities issued under the Private Placement have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. The Company plans to file a registration statement pursuant to the U.S. Securities Act which, when effective, will permit the resale of the Common Shares issued in connection with the Private Placement as well as the Common Shares issuable upon exercise of the Warrants. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of Silver Bull’s securities in the United States.

About Silver Bull: Silver Bull is a Vancouver-based mineral exploration company whose shares are listed on the TSX and trade on the OTCQB in the United States. Silver Bull recently signed an Option Agreement to acquire the Beskauga Copper-Gold Project, located in North Eastern Kazakhstan. This agreement is subject to on the ground due diligence, which will occur once safe travel to the region is allowed due to current COVID-19 related restrictions. In addition, Silver Bull owns the Sierra Mojada Project which is located 150 kilometers north of the city of Torreon in Coahuila, Mexico, and is highly prospective for silver and zinc. Sierra Mojada is currently under a joint venture option with South32 International Investment Holdings Pty Ltd.

On behalf of the Board of Directors “Tim Barry”

Tim Barry, CPAusIMM Chief Executive Officer, President and Director

INVESTOR RELATIONS: +1 604 687 5800 [email protected]  

Cautionary note regarding forward looking statements: Certain statements in this news release are “forward-looking” within the meaning of applicable securities legislation. Forward-looking statements can generally be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. Forward-looking statements include, but are not limited to, statements relating to the expected use of proceeds from the Private Placement and the anticipated closing date for the second tranche of the Private Placement. Forward-looking statements are necessarily based upon the current belief, opinions and expectations of management that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and other contingencies. Many factors could cause the Company’s actual results to differ materially from those expressed or implied in the forward-looking statements. These factors include, among others, market prices, metal prices, availability of capital and financing, general economic, market or business conditions, as well as other risk factors set out under the heading “Risk Factors” in the Annual Report on Form 10-K for the year ended October 31, 2019, which is available on SEDAR at Investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Primary Logo

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News12 mins ago

VentureIsrael Launches New Venture Capital Fund

VentureIsrael announced today the launch of a new venture capital fund, which will invest in Israel based, early stage deep-tech...

gbafNews28 gbafNews28
News20 mins ago

Silver Bull Announces Closing of Initial Tranche of Private Placement For US$1.70 Million


gbafNews28 gbafNews28
News20 mins ago

Global Artificial Ligaments and Tendons Market- Featuring Artelon, Cousin-Biotech, FX Solutions, and GROUP FH ORTHO Among Others

The artificial ligaments and tendons market is poised to grow by USD 15.54 million during 2020-2024, progressing at a CAGR...

gbafNews28 gbafNews28
News40 mins ago

The U.S. EPA Announces New 5-Year Registration for XtendiMax® Herbicide, Bayer’s Low-Volatility Dicamba Product

Today, the U.S. Environmental Protection Agency (EPA) announced a new 5-year registration for XtendiMax herbicide with VaporGrip Technology, an important...

gbafNews28 gbafNews28
News48 mins ago

Visa to Acquire YellowPepper

Visa Inc. (NYSE: V) today announced it has signed a definitive agreement to acquire YellowPepper, a fintech pioneer with proprietary...

gbafNews28 gbafNews28
News50 mins ago

Joseph R. Biden Named Winner of Nickelodeon’s Kids Pick the President “Kids’ Vote”

The votes are in and kids have chosen Joseph R. Biden as the winner of Nickelodeons 2020 Kids Pick the...

gbafNews28 gbafNews28
News1 hour ago

PlanetWatch activates innovative air quality monitoring in two key Italian cities and announces grant from the Algorand Foundation

ST. GENIS-POUILLY, France, Oct. 28, 2020 /PRNewswire/ — PlanetWatch, a French startup which is leveraging the Algorand blockchain to build...

gbafNews28 gbafNews28
News1 hour ago

Atlas Crest Investment Corp. Announces Pricing of $500 Million Initial Public Offering

October 27, 2020 — Atlas Crest Investment Corp. (NYSE: ACIC.U, the “Company”) announced today that it priced its initial public...

gbafNews28 gbafNews28
News1 hour ago

Global Hemophilia Therapeutics Market- Featuring Bayer AG, CSL Ltd., F. Hoffmann-La Roche Ltd. Among Others

The hemophilia therapeutics market is poised to grow by USD 4.19 billion during 2020-2024 progressing at a CAGR of over...

gbafNews28 gbafNews28
News1 hour ago

Washington Federal Announces 22 Cent Per Share Cash Dividend

Today, the Board of Directors of Washington Federal, Inc. (Nasdaq: WAFD) (the Company), parent company of Washington Federal Bank, National...